Navigation Links
Adaptive Trial Paper Explores Benefits of Adaptive Trials for Phase I, Phase II Studies
Date:2/2/2010

Adaptive trial design is a hot topic in the drug development community thanks to their complexity and substantial potential benefits for sponsors and patients. In Medelis' new issue of Peer Perspectives in Oncology, Dr. Ranganath Nayak of Cytel Inc. discusses the rapid evolution of the adaptive trial model and the latest thinking about its application in phase I and phase II clinical studies.

Phoenix AZ (PRWEB) February 2, 2010 -- Adaptive trial design is a hot topic in the drug development community thanks to their complexity and substantial potential benefits for sponsors and patients. In Medelis' new issue of Peer Perspectives in Oncology, Dr. Ranganath Nayak of Cytel Inc. discusses the rapid evolution of the adaptive trial model and the latest thinking about its application in phase I and phase II clinical studies.

"When the industry started seriously talking about adaptive trial design a few years back, the focus was on phase III and seamless phase II/III trials," explains Medelis CEO Bob Bosserman. "But it turns out that the real action today is in phase II dose-finding trials and even in phase I trials for safety.

"Cytel has designed more adaptive trials for industry sponsors than any other service provider and in virtually every therapeutic area," he continued. "Sponsors should carefully consider the adaptive model for the many commercial, ethical, and budgetary benefits that the paper explores."

In the interview, Dr. Nayak, the CEO of Cytel, explains why adaptive trial design is gaining so much momentum in early stage studies. "First, adaptive trials are most helpful when you do not know enough at the beginning of a trial to design it with confidence," he says. "This is much more likely to be true in phases I and II than in phase III.

"Second, the best way to make expensive phase III trials more successful is to do more thorough work in phases I and II," he continues. "Getting the dose right through well-designed phase I and phase II trials is the best way to maximize success in phase III, which then leads to a higher rate of NDAs.

Dr. Nayak offers insight and expertise on a variety of issues surrounding adaptive trial design, including:

 
  • Commercial, ethical, and budgetary benefits of the adaptive trial model;
  • Statistical and data issues;
  • Changing to the adaptive model across multiple sites;
  • Safety issues to consider;
  • Budgeting for an adaptive trial;
  • Dealing with independent decision-making bodies;
  • Patient consent and communication issues;
  • Medical supply logistics;
  • Other best practices and planning issues.

The abstract is free and available for download at Medelis.com.

ABOUT "INSIDER ABSTRACTS"

This abstract is the sixth in Medelis' complimentary "Peer Perspectives in Oncology" Q&A series, which brings together respected researchers to discuss issues that face Chief Medical Officers today: rising costs, optimum patient accrual, targeted therapeutics, patient safety, FDA regulations, efficacy, budgets, and timelines. Previous issues include "Context of Vulnerability," "The Lost Opportunity in Phase I Oncology Trials," "Preclinical Trials: A Nuanced Approach to Get Into the Clinic Faster," "The Complete Phase IB," and "Patient Safety in Clinical Trials."

These free abstracts are available for download at http://www.medelis.com.

ABOUT CYTEL

Cytel, Inc., is a leading provider of clinical trial services and specialized statistical software for the biopharmaceutical, medical device, academic, and government research markets. Cytel has designed more adaptive trials for industry sponsors than any other service provider and in virtually every therapeutic area, helping pharmaceutical and biotech companies raise trial success rates while reducing development time and costs. The methods developed at Cytel are validated and published, with their authors regularly invited speakers on a range of adaptive topics including advances in Bayesian and Frequentist methods, adaptive trial modeling and simulation, key operational areas such as flexible randomization, forecasting of recruitment, and drug supply management. Cytel experts also periodically provide training to FDA biostatisticians on the use of Cytel's software.

ABOUT MEDELIS

Medelis, Inc. is an oncology contract research organization providing a total solution for biotechnology and pharmaceutical companies seeking rapid drug development and approval. Medelis' medical founders, team physicians and clinical trial management physicians, including Dan Von Hoff, James Gourzis and Michael Gordon, are internationally-recognized oncology thought and opinion leaders who understand the future of personalized medicine and threshold of credibility trials.

Medelis is privately-held with US locations in Phoenix (headquarters), Nashville, Boston and Reno. Medelis Europe is headquartered in Port Vendres, France.

###

Read the full story at http://www.prweb.com/releases/cro/phaseI-phaseII/prweb3540304.htm.


'/>"/>
Source: PRWeb
Copyright©2010 Vocus, Inc.
All rights reserved  

Related biology technology :

1. United BioSource Acquires Interest in Leading Adaptive Design Technology Service Provider
2. Siemens Expands the SOMATOM Definition(TM) Line With Worlds First Adaptive CT Scanner
3. Truman Medical Centers Becomes One of the First Hospitals in the U.S. To Install the Worlds First Adaptive 128-slice CT Scanner
4. ClearTrial to Chair Session at DIA 45th Annual Meeting on "Effective Operational Planning for Adaptive Clinical Trials"
5. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
6. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
7. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
8. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
9. PNH Patients Treated with Soliris(TM) Experienced Dramatic Reduction in Blood Clots During Clinical Trials
10. YM BIOSCIENCES, EUROPEAN PARTNER, ONCOSCIENCE AG, ANNOUNCES INITIATION OF ADVANCED NIMOTUZUMAB TRIALS IN ADULT GLIOMA AND PANCREATIC CANCER
11. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Adaptive Trial Paper Explores Benefits of Adaptive Trials for Phase I, Phase II Studies 
(Date:3/23/2017)... NEW YORK , March 23, 2017 ... closer look at four equities in the Biotech industry: ... EYEG), Synthetic Biologics Inc. (NYSE MKT: SYN), and Regulus ... March 21 st , 2017, Credit Suisse upgraded its rating ... stocks by downloading their free report at: ...
(Date:3/22/2017)... , ... March 22, 2017 , ... ... human tissue regeneration from small lab samples to full-size tissues, bones, even whole ... establish a vascular system that delivers blood deep into the developing tissue. ...
(Date:3/22/2017)... 2017 Good Start Genetics, a leading family ... 130 million covered lives mark through its most recent ... Texas . With newly signed contracts nationally and ... strong payor acceptance based on the quality of its ... counseling, its industry-leading customer care and support and its ...
(Date:3/22/2017)... New York , March 22, 2017 ... is largely fragmented, states a research report by Transparency ... S.A., Pfizer Inc., Amgen Inc., and AbbVie Inc., accounted ... in 2015. The prominent players in this market are ... expand their product portfolio, which is likely to lead ...
Breaking Biology Technology:
(Date:3/2/2017)... 2017 Summary This report provides ... KGaA and its partnering interests and activities since 2010. ... Description The Partnering Deals and Alliance since 2010 report ... one of the world,s leading life sciences companies. ... to ensure inclusion of the most up to date ...
(Date:2/28/2017)... -- News solutions for biometrics, bag drop and New ... At ... 16 March, Materna will present its complete end-to-end passenger journey, ... a real benefit for passengers. To accelerate the whole passenger ... point solutions to take passengers through the complete integrated process ...
(Date:2/22/2017)... Feb. 22, 2017 With the biometrics ... Research identifies four technologies that innovative and agile ... significant share in the changing competitive landscape: multifactor ... authentication.   "Companies can no longer ... security," says Dimitrios Pavlakis , Industry Analyst ...
Breaking Biology News(10 mins):